napabucasin + irinotecan

Napabucasin + irinotecan is an investigational combination therapy for cancer, particularly evaluated in metastatic colorectal cancer (CRC). **Napabucasin** is an orally administered small molecule and NAD(P)H:quinone oxidoreductase 1 (NQO1) bioactivatable agent that generates reactive oxygen species, disrupts multiple oncogenic pathways (including STAT3 signaling), inhibits cancer stemness properties, and induces cancer cell death. **Irinotecan** is an intravenous topoisomerase I inhibitor that prevents DNA re-ligation in cancer cells, causing DNA damage and apoptosis. The combination is researched as part of chemotherapy regimens (such as FOLFIRI) to improve efficacy in treating metastatic colorectal and other solid tumors[4][6][9].